2021
Design and rationale of the colchicine/statin for the prevention of COVID-19 complications (COLSTAT) trial
Shah T, McCarthy M, Nasir I, Archer H, Ragheb E, Kluger J, Kashyap N, Paredes C, Patel P, Lu J, Kandel P, Song C, Khan M, Ul Haq F, Ahmad R, Howes C, Cambi B, Lancaster G, Cleman M, Dela Cruz CS, Parise H, Lansky A. Design and rationale of the colchicine/statin for the prevention of COVID-19 complications (COLSTAT) trial. Contemporary Clinical Trials 2021, 110: 106547. PMID: 34461322, PMCID: PMC8397504, DOI: 10.1016/j.cct.2021.106547.Peer-Reviewed Original ResearchConceptsHospitalized COVID-19 patientsCOVID-19 patientsStandard of careElectronic health recordsComplications TrialSevere COVID-19 diseaseWorld Health Organization (WHO) ordinal scaleVenous thromboembolic eventsHealth recordsCombination of colchicineRates of morbidityCOVID-19 diseaseCost-effective treatmentPrimary endpointRespiratory failureThromboembolic eventsClinical improvementMyocardial injuryPragmatic trialClinical trialsPatientsEvent ascertainmentHealth NetworkRosuvastatinTrials
2006
Prognostic Implications of Creatine Kinase Elevation After Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction
Halkin A, Stone GW, Grines CL, Cox DA, Rutherford BD, Esente P, Meils CM, Albertsson P, Farah A, Tcheng JE, Lansky AJ, Mehran R. Prognostic Implications of Creatine Kinase Elevation After Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction. Journal Of The American College Of Cardiology 2006, 47: 951-961. PMID: 16516077, DOI: 10.1016/j.jacc.2005.12.003.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionAcute myocardial infarctionPrimary PCIPercutaneous coronary interventionCreatine kinase elevationCoronary interventionPrognostic implicationsMyocardial infarctionCK levelsLate Angioplasty Complications (CADILLAC) trialLeft ventricular ejection fractionOne-year survivorsPost-PCI ThrombolysisMyocardial infarction (TIMI) flowOne-year mortalityAntegrade blood flowVentricular ejection fractionPeak creatine kinaseCK monitoringControlled AbciximabComplications TrialMost patientsEjection fractionIndependent predictorsMortality independent
2005
Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction: Results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial
Lansky A, Piedras C, Costa R. Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction: Results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. ACC Current Journal Review 2005, 14: 44-45. DOI: 10.1016/j.accreview.2005.08.053.Peer-Reviewed Original ResearchImpact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction
Prasad A, Stone GW, Stuckey TD, Costantini CO, Zimetbaum PJ, McLaughlin M, Mehran R, Garcia E, Tcheng JE, Cox DA, Grines CL, Lansky AJ, Gersh BJ. Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction. Journal Of The American College Of Cardiology 2005, 45: 508-514. PMID: 15708696, DOI: 10.1016/j.jacc.2004.10.054.Peer-Reviewed Original ResearchConceptsPrimary PCIPrimary percutaneous coronary interventionST-segment elevation resolutionMyocardial blush gradeAcute myocardial infarctionDiabetes mellitusMyocardial perfusionMyocardial infarctionIndependent predictorsGrade 3Late Angioplasty Complications (CADILLAC) trialTIMI flow grade 3Infarct-related arteryAbnormal myocardial perfusionPercutaneous coronary interventionAbciximab administrationControlled AbciximabPostprocedural ThrombolysisBlush gradePrimary angioplastyComplications TrialCoronary interventionReperfusion successMyocardial reperfusionPoor prognosis
2004
Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial)
Dangas G, Aymong ED, Mehran R, Tcheng JE, Grines CL, Cox DA, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Lansky AJ, Stone GW, Investigators F. Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial). The American Journal Of Cardiology 2004, 94: 983-988. PMID: 15476608, DOI: 10.1016/j.amjcard.2004.06.050.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionPercutaneous coronary interventionAcute myocardial infarctionMajor adverse cardiac eventsAdverse cardiac eventsEarly thrombosisAbciximab usePrimary stentingPrimary angioplastyCardiac eventsBalloon angioplastyMyocardial infarctionBalloon diameterLate Angioplasty Complications (CADILLAC) trialRepeat target vessel revascularizationRepeat coronary angioplastyTarget vessel revascularizationHigh rateControlled AbciximabVessel revascularizationAngiographic morphologyClinical determinantsComplications TrialControl patientsCoronary interventionPrognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarctionThe controlled abciximab and device investigation to lower late angioplasty complications (CADILLAC) trial
MCLAUGHLIN M, STONE G, AYMONG E, GARDNER G, MEHRAN R, LANSKY A, GRINES C, TCHENG J, COX D, STUCKEY T. Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarctionThe controlled abciximab and device investigation to lower late angioplasty complications (CADILLAC) trial. Journal Of The American College Of Cardiology 2004, 44: 1215-1223. DOI: 10.1016/s0735-1097(04)01330-0.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCoronary AngiographyCoronary CirculationElectrocardiographyFemaleHeart Conduction SystemHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPostoperative ComplicationsPredictive Value of TestsPrognosisProspective StudiesRecurrenceRisk FactorsStatistics as TopicSurvival AnalysisTreatment OutcomePrognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction The controlled abciximab and device investigation to lower late angioplasty complications (CADILLAC) trial
McLaughlin M, Stone G, Aymong E, Gardner G, Mehran R, Lansky A, Grines C, Tcheng J, Cox D, Stuckey T, Garcia E, Guagliumi G, Turco M, Josephson M, Zimetbaum P. Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction The controlled abciximab and device investigation to lower late angioplasty complications (CADILLAC) trial. Journal Of The American College Of Cardiology 2004, 44: 1215-1223. PMID: 15364322, DOI: 10.1016/j.jacc.2004.06.053.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCoronary AngiographyCoronary CirculationElectrocardiographyFemaleHeart Conduction SystemHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPostoperative ComplicationsPredictive Value of TestsPrognosisProspective StudiesRecurrenceRisk FactorsStatistics as TopicSurvival AnalysisTreatment OutcomeConceptsST-segment elevation resolutionPrimary percutaneous coronary interventionPrimary PCIST-segment elevationAcute myocardial infarctionLate Angioplasty Complications (CADILLAC) trialMaximum ST-segment elevationCombined end pointComplications TrialMyocardial infarctionBaseline ST-segment elevationEnd pointInfarct-related artery patencyHigh-risk categorizationPost-PCI electrocardiogramsST-segment resolutionPercutaneous coronary interventionTarget vessel patencyStrong independent predictorControlled AbciximabPrimary angioplastyArtery patencyCoronary interventionIndependent predictorsPrognostic utilityImpact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention Analysis from the controlled abciximab and device investigation to lower late angioplasty complications (cadillac) trial
Nikolsky E, Aymong ED, Halkin A, Grines CL, Cox DA, Garcia E, Mehran R, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Cohen DA, Negoita M, Lansky AJ, Stone GW. Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention Analysis from the controlled abciximab and device investigation to lower late angioplasty complications (cadillac) trial. Journal Of The American College Of Cardiology 2004, 44: 547-553. PMID: 15358018, DOI: 10.1016/j.jacc.2004.03.080.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAnemiaAngioplasty, Balloon, CoronaryAntibodies, MonoclonalBlood Component TransfusionFemaleHematocritHemorrhageHospital MortalityHumansImmunoglobulin Fab FragmentsIncidenceMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPlatelet Aggregation InhibitorsPredictive Value of TestsPrognosisRandomized Controlled Trials as TopicStentsStrokeSurvival AnalysisTreatment OutcomeConceptsPrimary percutaneous coronary interventionAcute myocardial infarctionPrimary PCILate Angioplasty Complications (CADILLAC) trialImpact of anemiaComplications TrialMyocardial infarctionWorld Health Organization criteriaPrimary PCI outcomesBlood product transfusionOne-year mortalityBaseline laboratory valuesPercutaneous coronary interventionPresence of anemiaBaseline anemiaControlled AbciximabHospital mortalityProduct transfusionHemorrhagic complicationsIndex hospitalizationCoronary interventionIndependent predictorsPCI outcomesPrognostic importanceAdverse outcomesImpact of intravenous Beta-Blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction
Halkin A, Grines CL, Cox DA, Garcia E, Mehran R, Tcheng JE, Griffin JJ, Guagliumi G, Brodie B, Turco M, Rutherford BD, Aymong E, Lansky AJ, Stone GW. Impact of intravenous Beta-Blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. Journal Of The American College Of Cardiology 2004, 43: 1780-1787. PMID: 15145099, DOI: 10.1016/j.jacc.2003.10.068.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionAcute myocardial infarctionPrimary PCIBeta-blocker useMyocardial recoveryMyocardial infarctionLate Angioplasty Complications (CADILLAC) trialOral beta-blocker medicationOral beta-blocker useLeft ventricular ejection fractionIntravenous beta blockadeMechanical reperfusion therapyAbsence of contraindicationsBeta-blocker therapyBeta-blocker medicationBeta-blocker administrationPercutaneous coronary interventionVentricular ejection fractionBeta blockadeControlled AbciximabPrimary angioplastyReperfusion therapyComplications TrialCoronary interventionSurvival benefitImportance of mitral regurgitation inpatients undergoing percutaneous coronaryintervention for acute myocardial infarction The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial
Pellizzon GG, Grines CL, Cox DA, Stuckey T, Tcheng JE, Garcia E, Guagliumi G, Turco M, Lansky AJ, Griffin JJ, Cohen DJ, Aymong E, Mehran R, O'Neill WW, Stone GW. Importance of mitral regurgitation inpatients undergoing percutaneous coronaryintervention for acute myocardial infarction The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. Journal Of The American College Of Cardiology 2004, 43: 1368-1374. PMID: 15093869, DOI: 10.1016/j.jacc.2003.11.046.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalFemaleHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMitral Valve InsufficiencyMyocardial InfarctionPlatelet Aggregation InhibitorsPrognosisProspective StudiesSeverity of Illness IndexStentsSurvival AnalysisTreatment OutcomeConceptsAcute myocardial infarctionLeft ventricular ejection fractionMechanical reperfusion therapySevere mitral regurgitationMitral regurgitationIndex procedureReperfusion therapyIndependent predictorsMyocardial infarctionLate Angioplasty Complications (CADILLAC) trialPresence of MRHigher Killip classMechanical reperfusion strategiesNon-shock patientsHigh-risk patientsLong-term mortalityTriple vessel diseasePercutaneous coronary interventionVentricular ejection fractionMild mitral regurgitationControlled AbciximabKillip classReperfusion strategyComplications TrialCoronary intervention
2003
Outcomes of optimal or “stent-like”balloon angioplasty in acutemyocardial infarction: the CADILLAC trial
Cox DA, Stone GW, Grines CL, Stuckey T, Cohen DJ, Tcheng JE, Garcia E, Guagliumi G, Iwaoka RS, Fahy M, Turco M, Lansky AJ, Griffin JJ, Mehran R, Investigators C. Outcomes of optimal or “stent-like”balloon angioplasty in acutemyocardial infarction: the CADILLAC trial. Journal Of The American College Of Cardiology 2003, 42: 971-977. PMID: 13678914, DOI: 10.1016/s0735-1097(03)00911-2.Peer-Reviewed Original ResearchConceptsPercutaneous transluminal coronary angioplastyAcute myocardial infarctionTarget vessel revascularizationIschemic target vessel revascularizationRoutine stentingRoutine stent placementStent implantationStent placementPrimary percutaneous transluminal coronary angioplastyComposite adverse event rateLate Angioplasty Complications (CADILLAC) trialRoutine stent implantationAdverse event ratesTransluminal coronary angioplastyRelevant treatment modalitiesRate of deathCADILLAC trialControlled AbciximabEligible lesionsAngiographic restenosisVessel revascularizationComplications TrialCoronary angioplastyDiameter stenosisPTCA results